NG

Nenad Grmusa

Chief Executive Officer

DEM Biopharma, Inc.

Cambridge, Massachusetts


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
DEM Biopharma, Inc.
Industry
research
Employees
25.0
Seniority
C suite
Annual Revenue
120000.0
Total Funding
70000000.0
Latest Funding
Other

Technologies

Outlook Greenhouse.io BambooHR Google Font API Google Tag Manager WordPress.org Mobile Friendly

Keywords

biotechnology research innate immune system solid organ malignancies biopharmaceutical company immune evasion therapeutic targets genome-wide crispr immuno-oncology first-in-class targets hemathology clinical trial drug discovery bioprocess development crispr technology immune checkpoints targeted therapies cancer immunotherapy preclinical studies biologics biomanufacturing drug product stability chemistry manufacturing controls cell therapy molecular biology oncology research personalized medicine in vitro studies pharmaceutical pipelines clinical development novel therapeutics genetics immune response modulation translational medicine pharmaceutical consultancy biotechnology investments therapeutic modalities emerging science early-stage biotech diagnostic assays drug candidate fda approval scientific advisory pharmacology research biotech innovation human immune response cancer research dendritic cell biology cancer treatment novel drug formation pharmaceutical development hemato-oncology

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans